Navigation Links
Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant

Addition of Timothy Forsey, PhD, Further Strengthens Kendle's Global

Regulatory Affairs Organization

CINCINNATI, Aug. 10 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced that Timothy Forsey, PhD, has joined the company as Principal Regulatory Affairs Consultant specializing in providing regulatory affairs guidance to the company's biotechnology customers. Based in Kendle's Ely, Cambridgeshire, England office, he will work with customers to gain regulatory approval for both new marketing authorizations and changes to existing marketing authorizations. Dr. Forsey will provide customers with advice on strategy and regulatory approaches to development, interact on their behalf with regulatory agencies and assist them with dossier preparation.

(Logo: )

"As biotechnology's overall contribution to the health care arena continues to grow, so will the demand for outsourcing services, as new therapies move from preclinical to the clinical phases of drug development," said Melanie Bruno, PhD, Vice President Global Regulatory Affairs and Quality. "Tim Forsey's experience with this customer group and in the regulatory environment will be a tremendous asset to our biotech and pharmaceutical customers seeking to move their new compounds from discovery to market approval," she added.

Dr. Forsey previously served as Head of Biologicals and the Biotechnology Unit for The Medicines and Healthcare products Regulatory Agency (MHRA), where he was involved with a variety of licensing and scientific issues, and represented the United Kingdom on the Biologics Working Party of the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMEA). He also worked as Senior Director, Head of European Regulatory Affairs for Shire Human Genetic Therapies, Ltd. Prior to that, Dr. Forsey worked for Pharmacia, Amgen, the National Institute for Biological Standards and Control and the University of London. In all, he brings more than 30 years of pharmaceutical, governmental and research experience to his role with Kendle.

Dr. Forsey earned a doctorate in microbiology from the University of London and a Bachelor of Science in microbiology from the University of Surrey, England. A widely-published author, he is a registered member of The Organisation for Professionals in Regulatory Affairs (TOPRA) and the Drug Information Association (DIA).

Dr. Forsey is the latest member of an international team of pharmaceutical, clinical and non-clinical biotechnology experts Kendle has assembled with backgrounds encompassing regulatory agencies on three continents, as well as experience working for a variety of pharmaceutical companies and academic and research institutions.

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is among the world's leading global clinical research organizations and is the fourth-largest provider of Phase II-IV clinical development services worldwide. We deliver innovative and robust clinical development solutions - from first-in-human studies through market launch and surveillance - to help the world's biopharmaceutical companies maximize product life cycles and grow market share.

Our global clinical development business is focused on five regions - North America, Europe, Asia/Pacific, Latin America and Africa - to meet customer needs. With the expertise of our more than 3,000 associates worldwide, Kendle has conducted clinical trials and provided regulatory and pharmacovigilance services in more than 80 countries. The company was named the "Top CRO to Work With" in the Thomson CenterWatch 2007 Survey of U.S. Investigative Sites.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 1200, Cincinnati, OH 45202 or from the Company's Web site at

Forward-Looking Statements

This release contains information about management's view of Kendle's future expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including, but not limited to, those set forth in the "Risk Factors" section of the Company's latest Form 10-K and other filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point, the Company specifically disclaims any obligation to do so other than as required by federal securities laws. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this press release.

SOURCE Kendle International Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Kendle to Ring Opening Bell at NASDAQ Stock Market on August 22
2. Kendle Marks 10th Anniversary as Public Company With NASDAQ Opening Bell Ceremony and Investor Day Event
3. Kendle to Present at Thomas Weisel Partners Healthcare Conference 2007
4. Kendle to Present at Bear Stearns 20th Annual Healthcare Conference
5. Kendle to Present at the UBS Global Life Sciences Conference
6. Kendle to Present at the Natixis Bleichroeder Hidden Gems Conference
7. Kendle Invites You to Attend Its Third Quarter 2007 Earnings Conference Call and Webcast
8. Kendle Named Best CRO for Second Consecutive Year by Leading Global Pharmaceutical Publication Scrip
9. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
10. Codexis Appoints Singapore Laboratories Managing Director
11. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
Post Your Comments:
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free ... and will showcase its product’s latest features from June 26 to June 30, ... poster on Disrupting Clinical Trials in The Cloud during the conference. DIA ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, ... tools designed, tuned and optimized exclusively for Okuma CNC machining centers at The ... of a collaboration among several companies with expertise in toolholding, cutting tools, machining ...
(Date:6/23/2016)... 23, 2016 adds ... to its pharmaceuticals section with historic and forecast ... much more. Complete report on the ... profiling 15 companies and supported with 261 tables ... . The Global Cell Culture ...
(Date:6/22/2016)... Research and Markets has announced the addition of the "Biomarkers: ... The global biomarkers market has grown ... market is expected to grow at a five-year compound annual growth ... billion in 2015 to $96.6 billion in 2020. ... 2020) are discussed. As well, new products approved in 2013 and ...
Breaking Biology Technology:
(Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)... DUBLIN , April 15, 2016 ... of the,  "Global Gait Biometrics Market 2016-2020,"  report ... ) , ,The global gait ... CAGR of 13.98% during the period 2016-2020. ... movement angles, which can be used to compute ...
Breaking Biology News(10 mins):